← Back

Wire · opportunities

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with ...

Published

8 September 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at abbott.mediaroom.com

Verified

Fusion42 · 8 September 2026 · Fusion42 review

Abbott has received FDA approval for its TactiFlex™ Duo Ablation Catheter, a device combining pulsed field ablation and radiofrequency energy to treat complex atrial fibrillation cases with flexible, precision therapy. The approval is supported by positive clinical data from the FlexPulse IDE study and enhances Abbott's cardiac ablation technology portfolio.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.

◆ The Wire takeaway

Physicians treating complex AFib gain a new flexible tool that blends two ablation methods, raising expectations for tailored therapies. You should prepare to engage cardiologists adapting to dual-energy ablation tech as the procedure grows commercially.

Coverage

3 sources · 8 Sep 2026

Related on Wire

Topics

Medtechfda-approvalcardiac-ablationatrial-fibrillationmedtechclinical-evidenceabbott